,22 MASH-HCC (previously NASH-HCC) was investigated across several mouse models, and MASH-affected livers were found to have an increased frequency of CD8 + PD1 + T cells compared to controls; treatment with immunotherapy paradoxically did not lead to tumor regression but instead exacerbated liver fibrosis and increased incidence of HCC in mice.23 This evidence concerns the gene CD8A and Hepatic fibrosis.